{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:53Z","timestamp":1707524333775},"reference-count":111,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,24]]},"DOI":"10.7759\/cureus.19009","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T17:49:02Z","timestamp":1635097742000},"source":"Crossref","is-referenced-by-count":2,"title":["Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome"],"prefix":"10.7759","author":[{"given":"Shreya","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaalina","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishab","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaithanya","family":"Avanthika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Samayam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maanya R","family":"Katta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pahel","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000022492","article-title":"Antiphospholipid-thrombosis syndromes","volume":"29","author":"Bick RL","year":"1999","unstructured":"Bick RL, Arun B, Frenkel EP. Antiphospholipid-thrombosis syndromes. Haemostasis. 1999, 29:100-10. 10.1159\/000022492","journal-title":"Haemostasis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14017","article-title":"Use of direct oral anticoagulants in antiphospholipid syndrome","volume":"16","author":"Cohen H","year":"2018","unstructured":"Cohen H, Efthymiou M, Isenberg DA. Use of direct oral anticoagulants in antiphospholipid syndrome. J Thromb Haemost. 2018, 16:1028-39. 10.1111\/jth.14017","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.40901","article-title":"The epidemiology of antiphospholipid syndrome: a population-based study","volume":"71","author":"Duarte-Garc\u00eda A","year":"2019","unstructured":"Duarte-Garc\u00eda A, Pham MM, Crowson CS, et al.. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol. 2019, 71:1545-52. 10.1002\/art.40901","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"Rodr\u00edguez-Pint\u00f3 I","year":"2018","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford). 2018, 57:1264-70. 10.1093\/rheumatology\/key082","journal-title":"Rheumatology (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera R","year":"2002","unstructured":"Cervera R, Piette JC, Font J, et al.. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002, 46:1019-27. 10.1002\/art.10187","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.182204","article-title":"Venous thrombosis in the antiphospholipid syndrome","volume":"29","author":"Farmer-Boatwright MK","year":"2009","unstructured":"Farmer-Boatwright MK, Roubey RA. Venous thrombosis in the antiphospholipid syndrome. Arterioscler Thromb Vasc Biol. 2009, 29:321-5. 10.1161\/ATVBAHA.108.182204","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis S","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295-306. 10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.52","article-title":"Pathogenesis of antiphospholipid syndrome: understanding the antibodies","volume":"7","author":"Meroni PL","year":"2011","unstructured":"Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011, 7:330-9. 10.1038\/nrrheum.2011.52","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320950461","article-title":"16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends","volume":"29","author":"Cohen H","year":"2020","unstructured":"Cohen H, Cuadrado MJ, Erkan D, et al.. 16th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Lupus. 2020, 29:1571-93. 10.1177\/0961203320950461","journal-title":"Lupus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161364","article-title":"Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study","volume":"44","author":"Taraborelli M","year":"2017","unstructured":"Taraborelli M, Reggia R, Dall'Ara F, et al.. Longterm outcome of patients with primary antiphospholipid syndrome: a retrospective multicenter study. J Rheumatol. 2017, 44:1165-72. 10.3899\/jrheum.161364","journal-title":"J Rheumatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"Eriksson BI","year":"2009","unstructured":"Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009, 48:1-22. 10.2165\/0003088-200948010-00001","journal-title":"Clin Pharmacokinet"},{"key":"ref12","article-title":"The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies","volume":"16","author":"Fields RA","year":"1989","unstructured":"Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol. 1989, 16:623-5.","journal-title":"J Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"Andreoli L","year":"2013","unstructured":"Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken). 2013, 65:1869-73. 10.1002\/acr.22066","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri M","year":"2000","unstructured":"Petri M. Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun. 2000, 15:145-51. 10.1006\/jaut.2000.0409","journal-title":"J Autoimmun"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s1571-5078(08)00402-9","article-title":"Epidemiology of the antiphospholipid syndrome","author":"Mehrani T","unstructured":"Mehrani T, Petri M. Epidemiology of the antiphospholipid syndrome. Handbook of Systemic Autoimmune Diseases. 2009 (ed): Elsevier, Amsterdam; 13-34. 10.1016\/s1571-5078(08)00402-9"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.11.013","article-title":"The geoepidemiology of the antiphospholipid antibody syndrome","volume":"9","author":"Biggioggero M","year":"2010","unstructured":"Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010, 9:A299-304. 10.1016\/j.autrev.2009.11.013","journal-title":"Autoimmun Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(17)30066-X","article-title":"Antiphospholipid syndrome","volume":"151","author":"Cervera R","year":"2017","unstructured":"Cervera R. Antiphospholipid syndrome. Thromb Res. 2017, 151:S43-S47. 10.1016\/S0049-3848(17)30066-X","journal-title":"Thromb Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3 I","year":"2016","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016, 15:1120-4. 10.1016\/j.autrev.2016.09.010","journal-title":"Autoimmun Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.06.009","article-title":"Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry","volume":"6","author":"Cervera R","year":"2006","unstructured":"Cervera R, Espinosa G, Bucciarelli S, G\u00f3mez-Puerta JA, Font J. Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry. Autoimmun Rev. 2006, 6:81-4. 10.1016\/j.autrev.2006.06.009","journal-title":"Autoimmun Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-001-0030-5","article-title":"The epidemiology of the antiphospholipid syndrome: who is at risk?","volume":"3","author":"Finazzi G","year":"2001","unstructured":"Finazzi G. The epidemiology of the antiphospholipid syndrome: who is at risk?. Curr Rheumatol Rep. 2001, 3:271-6. 10.1007\/s11926-001-0030-5","journal-title":"Curr Rheumatol Rep"},{"key":"ref21","article-title":"Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals","volume":"31","author":"Gir\u00f3n-Gonz\u00e1lez JA","year":"2017","unstructured":"Gir\u00f3n-Gonz\u00e1lez JA, Garc\u00eda del R\u00edo E, Rodr\u00edguez C, Rodr\u00edguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2017, 31:1560-1567.","journal-title":"J Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(95)00247-o","article-title":"Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy","volume":"86","author":"Yasuda M","year":"1995","unstructured":"Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol. 1995, 86:555-559. 10.1016\/0029-7844(95)00247-o","journal-title":"Obstet Gynecol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00143.x","article-title":"Antiphospholipid antibodies in patients with preeclampsia","volume":"36","author":"Allen JY","year":"1996","unstructured":"Allen JY, Tapia-Santiago C, Kutteh WH. Antiphospholipid antibodies in patients with preeclampsia. Am J Reprod Immunol. 1996, 36:81-5. 10.1111\/j.1600-0897.1996.tb00143.x","journal-title":"Am J Reprod Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(99)70608-3","article-title":"High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia","volume":"180","author":"van Pampus MG","year":"1999","unstructured":"van Pampus MG, Dekker GA, Wolf H, Huijgens PC, Koopman MM, von Blomberg BM, B\u00fcller HR. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol. 1999, 180:1146-1150. 10.1016\/s0002-9378(99)70608-3","journal-title":"Am J Obstet Gynecol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.11.003","article-title":"Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry","volume":"124","author":"Roldan V","year":"2009","unstructured":"Roldan V, Lecumberri R, Mu\u00f1oz-Torrero JF, Vicente V, Rocha E, Brenner B, Monreal M. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res. 2009, 124:174-7. 10.1016\/j.thromres.2008.11.003","journal-title":"Thromb Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198507183130304","article-title":"Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus","volume":"313","author":"Lockshin MD","year":"1985","unstructured":"Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, Ferenc M. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med. 1985, 313:152-6. 10.1056\/NEJM198507183130304","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0015-0282(16)58565-3","article-title":"Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies","volume":"66","author":"Yetman DL","year":"1996","unstructured":"Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril. 1996, 66:540-6. 10.1016\/s0015-0282(16)58565-3","journal-title":"Fertil Steril"},{"key":"ref28","article-title":"Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience","volume":"80","author":"Branch DW","year":"1992","unstructured":"Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992, 80:614-20.","journal-title":"Obstet Gynecol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91477-4","article-title":"The antiphospholipid syndrome: ten years on","volume":"342","author":"Hughes GR","year":"1993","unstructured":"Hughes GR. The antiphospholipid syndrome: ten years on. Lancet. 1993, 342:341-44. 10.1016\/0140-6736(93)91477-4","journal-title":"Lancet"},{"key":"ref30","article-title":"Antiphospholipid antibodies: involvement of protein cofactors","volume":"78","author":"Galli M","year":"1993","unstructured":"Galli M, Barbui T, Zwaal RF, Comfurius P, Bevers EM. Antiphospholipid antibodies: involvement of protein cofactors. Antiphospholipid antibodies: involvement of protein cofactors. 1993, 78:1-4.","journal-title":"Antiphospholipid antibodies: involvement of protein cofactors"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.152.2.653","article-title":"The \ufb01fth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies","volume":"152","author":"Hunt J","year":"1994","unstructured":"Hunt J, Krilis S. The \ufb01fth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol. 1994, 152:653-9.","journal-title":"J Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1082267","article-title":"Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms","volume":"34","author":"Pierangeli SS","year":"2008","unstructured":"Pierangeli SS, Chen PP, Raschi E, et al.. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost. 2008, 34:236-50. 10.1055\/s-0028-1082267","journal-title":"Semin Thromb Hemost"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1002\/art.21009","article-title":"Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies","volume":"52","author":"Vega-Ostertag M","year":"2005","unstructured":"Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 2005, 52:1545-54. 10.1002\/art.21009","journal-title":"Arthritis Rheum"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand JH","year":"2010","unstructured":"Rand JH, Wu XX, Quinn AS, et al.. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010, 115:2292-9. 10.1182\/blood-2009-04-213520","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/0891693031000079257","article-title":"Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome","volume":"36","author":"Nagahama M","year":"2003","unstructured":"Nagahama M, Nomura S, Kanazawa S, Ozaki Y, Kagawa H, Fukuhara S. Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome. Autoimmunity. 2003, 36:125-31. 10.1080\/0891693031000079257","journal-title":"Autoimmunity"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.021444","article-title":"Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro","volume":"64","author":"Di Simone N","year":"2005","unstructured":"Di Simone N, Raschi E, Testoni C, et al.. Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis. 2005, 64:462-7. 10.1136\/ard.2004.021444","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2009.00717.x","article-title":"Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4\/MyD88 pathway","volume":"62","author":"Mulla MJ","year":"2009","unstructured":"Mulla MJ, Brosens JJ, Chamley LW, et al.. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4\/MyD88 pathway. Am J Reprod Immunol. 2009, 62:96-111. 10.1111\/j.1600-0897.2009.00717.x","journal-title":"Am J Reprod Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel H","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M, et al.. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013, 34:2094-106. 10.1093\/eurheartj\/eht134","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00298.x","article-title":"What is all that thrombin for?","volume":"1","author":"Mann KG","year":"2003","unstructured":"Mann KG, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost. 2003, 1:1504-14. 10.1046\/j.1538-7836.2003.00298.x","journal-title":"J Thromb Haemost"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza D","year":"2008","unstructured":"Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin. 2008, 24:2757-65. 10.1185\/03007990802361499","journal-title":"Curr Med Res Opin"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Weitz JI","year":"2012","unstructured":"Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e120S-51S. 10.1378\/chest.11-2294","journal-title":"Chest"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116404","article-title":"Importance of factor Xa in determining the procoagulant activity of whole-blood clots","volume":"91","author":"Eisenberg PR","year":"1993","unstructured":"Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993, 91:1877-83. 10.1172\/JCI116404","journal-title":"J Clin Invest"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415578172","article-title":"Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies","volume":"20","author":"Perzborn E","year":"2015","unstructured":"Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther. 2015, 20:554-62. 10.1177\/1074248415578172","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio M","year":"2005","unstructured":"Di Nisio M, Middeldorp S, B\u00fcller HR. Direct thrombin inhibitors. N Engl J Med. 2005, 353:1028-40. 10.1056\/NEJMra044440","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09233-2","article-title":"New antithrombotic agents","volume":"1804","author":"Hirsh J","year":"1999","unstructured":"Hirsh J, Weitz JI. New antithrombotic agents. Lancet. 1999, 1804:1431-1436. 10.1016\/S0140-6736(98)09233-2","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.09.013","article-title":"Use of anticoagulants in elderly patients","volume":"129","author":"Bauersachs RM","year":"2012","unstructured":"Bauersachs RM. Use of anticoagulants in elderly patients. Thromb Res. 2012, 129:107-15. 10.1016\/j.thromres.2011.09.013","journal-title":"Thromb Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2014.12.22933","article-title":"Anticoagulation drug therapy: a review","volume":"16","author":"Harter K","year":"2015","unstructured":"Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015, 16:11-7. 10.5811\/westjem.2014.12.22933","journal-title":"West J Emerg Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook A","year":"2012","unstructured":"Holbrook A, Schulman S, Witt DM, et al.. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e152S-84S. 10.1378\/chest.11-2295","journal-title":"Chest"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther MA","year":"2003","unstructured":"Crowther MA, Ginsberg JS, Julian J, et al.. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003, 349:1133-8. 10.1056\/NEJMoa035241","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"Guidelines on oral anticoagulation with warfarin - fourth edition","volume":"154","author":"Keeling D","year":"2011","unstructured":"Keeling D, Baglin T, Tait C, et al.. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011, 154:311-24. 10.1111\/j.1365-2141.2011.08753.x","journal-title":"Br J Haematol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315581207","article-title":"Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE","volume":"24","author":"Cohen H","year":"2015","unstructured":"Cohen H, Dor\u00e9 CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus. 2015, 24:1087-94. 10.1177\/0961203315581207","journal-title":"Lupus"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1364185","article-title":"Recent guidelines and recommendations for laboratory detection of lupus anticoagulants","volume":"40","author":"Moore GW","year":"2014","unstructured":"Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost. 2014, 40:163-71. 10.1055\/s-0033-1364185","journal-title":"Semin Thromb Hemost"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03555.x","article-title":"Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"7","author":"Pengo V","year":"2009","unstructured":"Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009, 7:1737-40. 10.1111\/j.1538-7836.2009.03555.x","journal-title":"J Thromb Haemost"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj YH","year":"2015","unstructured":"Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015, 11:967-77. 10.2147\/TCRM.S84210","journal-title":"Ther Clin Risk Manag"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1716752","article-title":"Satisfaction of patients with nonvitamin K anticoagulants compared to vitamin K antagonists: a systematic review and meta-analysis","volume":"121","author":"Katerenchuk V","year":"2021","unstructured":"Katerenchuk V, Duarte GS, Martins E Pereira G, et al.. Satisfaction of patients with nonvitamin K anticoagulants compared to vitamin K antagonists: a systematic review and meta-analysis. Thromb Haemost. 2021, 121:366-82. 10.1055\/s-0040-1716752","journal-title":"Thromb Haemost"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.11.037","article-title":"Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism","volume":"135","author":"Arachchillage DR","year":"2015","unstructured":"Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res. 2015, 135:388-93. 10.1016\/j.thromres.2014.11.037","journal-title":"Thromb Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.03.030","article-title":"Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome","volume":"135","author":"Efthymiou M","year":"2015","unstructured":"Efthymiou M, Lawrie AS, Mackie I, Arachchillage D, Lane PJ, Machin S, Cohen H. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thromb Res. 2015, 135:1191-7. 10.1016\/j.thromres.2015.03.030","journal-title":"Thromb Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera R","year":"2015","unstructured":"Cervera R, Serrano R, Pons-Estel GJ, et al.. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015, 74:1011-8. 10.1136\/annrheumdis-2013-204838","journal-title":"Ann Rheum Dis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo V","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, et al.. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018, 132:1365-71. 10.1182\/blood-2018-04-848333","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen H","year":"2016","unstructured":"Cohen H, Hunt BJ, Efthymiou M, et al.. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial. Lancet Haematol. 2016, 3:e426-36. 10.1016\/S2352-3026(16)30079-5","journal-title":"Lancet Haematol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros J","year":"2019","unstructured":"Ordi-Ros J, S\u00e1ez-Comet L, P\u00e9rez-Conesa M, et al.. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 2019, 171:685-94. 10.7326\/M19-0291","journal-title":"Ann Intern Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.04.009","article-title":"Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis","volume":"17","author":"Dufrost V","year":"2018","unstructured":"Dufrost V, Risse J, Reshetnyak T, et al.. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018, 17:1011-21. 10.1016\/j.autrev.2018.04.009","journal-title":"Autoimmun Rev"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou MG","year":"2019","unstructured":"Tektonidou MG, Andreoli L, Limper M, et al.. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019, 78:1296-304. 10.1136\/annrheumdis-2019-215213","journal-title":"Ann Rheum Dis"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16308","article-title":"Addendum to British Society for Haematology Guidelines on investigation and management of antiphospholipid syndrome, 2012 (Br J Haematol 2012; 157: 47-58): use of direct acting oral anticoagulants","volume":"189","author":"Arachchillage DR","year":"2020","unstructured":"Arachchillage DR, Gomez K, Alikhan R, Anderson JA, Lester W, Laffan M. Addendum to British Society for Haematology Guidelines on investigation and management of antiphospholipid syndrome, 2012 (Br J Haematol 2012; 157: 47-58): use of direct acting oral anticoagulants. Br J Haematol. 2020, 189:212-5. 10.1111\/bjh.16308","journal-title":"Br J Haematol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel TL","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, et al.. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020, 4:4693-738. 10.1182\/bloodadvances.2020001830","journal-title":"Blood Adv"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck W","year":"2011","unstructured":"Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011, 50:675-86. 10.2165\/11595320-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu311","article-title":"Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Vrijens B","year":"2015","unstructured":"Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015, 17:514-23. 10.1093\/europace\/euu311","journal-title":"Europace"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14001","article-title":"Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants","volume":"16","author":"Testa S","year":"2018","unstructured":"Testa S, Paoletti O, Legnani C, et al.. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2018, 16:842-8. 10.1111\/jth.14001","journal-title":"J Thromb Haemost"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122","volume":"21","author":"Goldhaber SZ","year":"2016","unstructured":"Goldhaber SZ, Eriksson H, Kakkar A, et al.. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122. Vasc Med. 2016, 21:506-14. 10.1177\/1358863X16668588","journal-title":"Vasc Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1177\/1076029617729214","article-title":"Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study","volume":"24","author":"Woller SC","year":"2018","unstructured":"Woller SC, Stevens SM, Kaplan DA, T Rondina M. Protocol modification of apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome study. Clin Appl Thromb Hemost. 2018, 24:192. 10.1177\/1076029617729214","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi S","year":"2017","unstructured":"Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017, 31:406-17. 10.1016\/j.blre.2017.07.006","journal-title":"Blood Rev"},{"key":"ref73","unstructured":"PRAC recommendations on signals. (2019). Accessed. October 24, 2021: https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/prac-recommendations-signals-adopted-8-11-april-2019-prac-...."},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza G","year":"2011","unstructured":"Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al.. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011, 20:206-18. 10.1177\/0961203310395803","journal-title":"Lupus"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.03.001","article-title":"Treatment of antiphospholipid syndrome beyond anticoagulation","volume":"206","author":"Dobrowolski C","year":"2019","unstructured":"Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin Immunol. 2019, 206:53-62. 10.1016\/j.clim.2018.03.001","journal-title":"Clin Immunol"},{"key":"ref76","article-title":"Anti-phospholipid Syndrome","author":"Erkan D","year":"2017","unstructured":"Erkan D, Salmon J, Lockshin M. Anti-phospholipid Syndrome. Kelley and Firestein's Textbook of Rheumatology. Firestein B, Gabriel M, O'Dell (ed): Elsevier, Philadelphia; 2017. 1389-1399."},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01516","article-title":"Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy","volume":"3","author":"Dentali F","year":"2005","unstructured":"Dentali F, Manfredi E, Crowther M, Ageno W. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005, 3:2121-2123. 10.1111\/j.1538-7836.2005.01516","journal-title":"J Thromb Haemost"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates SM","year":"2012","unstructured":"Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e691S-736S. 10.1378\/chest.11-2300","journal-title":"Chest"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7076.253","article-title":"Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)","volume":"314","author":"Rai R","year":"1997","unstructured":"Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997, 314:253-7. 10.1136\/bmj.314.7076.253","journal-title":"BMJ"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(96)70610-5","article-title":"Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone","volume":"174","author":"Kutteh WH","year":"1996","unstructured":"Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996, 174:1584-1589. 10.1016\/s0002-9378(96)70610-5","journal-title":"Am J Obstet Gynecol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002859.pub2","article-title":"Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant","author":"Empson M","year":"2005","unstructured":"Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005, CD002859. 10.1002\/14651858.CD002859.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.101463","article-title":"Antiphospholipid syndrome","volume":"34","author":"Sammaritano LR","year":"2020","unstructured":"Sammaritano LR. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol. 2020, 34:101463. 10.1016\/j.berh.2019.101463","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/art.22663","article-title":"Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals","volume":"56","author":"Erkan D","year":"2007","unstructured":"Erkan D, Harrison MJ, Levy R, et al.. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007, 56:2382-91. 10.1002\/art.22663","journal-title":"Arthritis Rheum"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1300522","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome","volume":"10","author":"Carmi O","year":"2017","unstructured":"Carmi O, Berla M, Shoenfeld Y, Levy Y. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol. 2017, 10:365-74. 10.1080\/17474086.2017.1300522","journal-title":"Expert Rev Hematol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri M","year":"2011","unstructured":"Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011, 13:77-80. 10.1007\/s11926-010-0141-y","journal-title":"Curr Rheumatol Rep"},{"key":"ref86","doi-asserted-by":"crossref","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","volume":"87","author":"Espinola RG","year":"2002","unstructured":"Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002, 87:518-22.","journal-title":"Thromb Haemost"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2870::aid-art475>3.0.co;2-y","article-title":"Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype","volume":"44","author":"Meroni PL","year":"2001","unstructured":"Meroni PL, Raschi E, Testoni C, et al.. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001, 44:12-2870. 10.1002\/1529-0131(200112)44:12&lt;2870::aid-art475&gt;3.0.co;2-y","journal-title":"Arthritis Rheum"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00896.x","article-title":"Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells","volume":"2","author":"Ferrara DE","year":"2004","unstructured":"Ferrara DE, Swerlick R, Casper K, Meroni PL, Vega-Ostertag ME, Harris EN, Pierangeli SS. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004, 2:1558-63. 10.1111\/j.1538-7836.2004.00896.x","journal-title":"J Thromb Haemost"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan D","year":"2013","unstructured":"Erkan D, Vega J, Ram\u00f3n G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013, 65:464-71. 10.1002\/art.37759","journal-title":"Arthritis Rheum"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn P","year":"2008","unstructured":"Kahn P, Ramanujam M, Bethunaickan R, et al.. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum. 2008, 58:2824-34. 10.1002\/art.23764","journal-title":"Arthritis Rheum"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2010.12.011","article-title":"Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation","volume":"84","author":"Huq FY","year":"2011","unstructured":"Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception. 2011, 84:128-32. 10.1016\/j.contraception.2010.12.011","journal-title":"Contraception"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665927","article-title":"Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use","volume":"127","author":"Martinelli I","year":"2016","unstructured":"Martinelli I, Lensing AW, Middeldorp S, et al.. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood. 2016, 127:1417-25. 10.1182\/blood-2015-08-665927","journal-title":"Blood"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137444","article-title":"Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin k antagonists: a systematic review and meta-analysis","volume":"10","author":"Skaistis J","year":"2015","unstructured":"Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin k antagonists: a systematic review and meta-analysis. PLoS One. 2015, 10:e0137444. 10.1371\/journal.pone.0137444","journal-title":"PLoS One"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti R","year":"2011","unstructured":"Nagarakanti R, Ezekowitz MD, Oldgren J, et al.. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011, 123:131-6. 10.1161\/CIRCULATIONAHA.110.977546","journal-title":"Circulation"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1586\/erc.11.62","article-title":"Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study)","volume":"9","author":"Romualdi E","year":"2011","unstructured":"Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther. 2011, 9:841-4. 10.1586\/erc.11.62","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000247","article-title":"Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism","volume":"26","author":"Sciascia S","year":"2015","unstructured":"Sciascia S, Breen K, Hunt BJ. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis. 2015, 26:476-7. 10.1097\/MBC.0000000000000247","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-04-0319","article-title":"Bleeding events with dabigatran or warfarin in patients with venous thromboembolism","volume":"115","author":"Majeed A","year":"2016","unstructured":"Majeed A, Goldhaber SZ, Kakkar A, et al.. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thromb Haemost. 2016, 115:291-8. 10.1160\/TH15-04-0319","journal-title":"Thromb Haemost"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1556046","article-title":"Management of bleeding associated with new oral anticoagulants","volume":"41","author":"Franchini M","year":"2015","unstructured":"Franchini M, Bonfanti C, Mannucci PM. Management of bleeding associated with new oral anticoagulants. Semin Thromb Hemost. 2015, 41:788-801. 10.1055\/s-0035-1556046","journal-title":"Semin Thromb Hemost"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.11-5-467","article-title":"The new oral anticoagulants","volume":"11","author":"Breen KA","year":"2011","unstructured":"Breen KA, Hunt BJ. The new oral anticoagulants. Clin Med (Lond). 2011, 11:467-9. 10.7861\/clinmedicine.11-5-467","journal-title":"Clin Med (Lond)"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejvs.2014.07.007","article-title":"New oral anticoagulants in the management of venous thromboembolism: a major advance?","volume":"48","author":"Sciascia S","year":"2014","unstructured":"Sciascia S, Hunt BJ. New oral anticoagulants in the management of venous thromboembolism: a major advance?. Eur J Vasc Endovasc Surg. 2014, 48:487-8. 10.1016\/j.ejvs.2014.07.007","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref101","unstructured":"Pradaxa 150 mg hard capsules. Summary of product characteristics (SPC). (2012). Accessed. October 24, 2021: https:\/\/www.medicines.org.uk\/emc\/product\/4703\/smpc."},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier J","year":"2008","unstructured":"Stangier J, St\u00e4hle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008, 47:47-59. 10.2165\/00003088-200847010-00005","journal-title":"Clin Pharmacokinet"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12599","article-title":"Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers","volume":"12","author":"Levi M","year":"2014","unstructured":"Levi M, Moore KT, Castillejos CF, et al.. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014, 12:1428-36. 10.1111\/jth.12599","journal-title":"J Thromb Haemost"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13115","article-title":"In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers","volume":"13","author":"Cheung YW","year":"2015","unstructured":"Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost. 2015, 13:1799-805. 10.1111\/jth.13115","journal-title":"J Thromb Haemost"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.01.017","article-title":"Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro","volume":"133","author":"Perzborn E","year":"2014","unstructured":"Perzborn E, Heitmeier S, Laux V, Buchm\u00fcller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res. 2014, 133:671-81. 10.1016\/j.thromres.2014.01.017","journal-title":"Thromb Res"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack CV Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, et al.. Idarucizumab for dabigatran reversal. N Engl J Med. 2015, 373:511-20. 10.1056\/NEJMoa1502000","journal-title":"N Engl J Med"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2014.11.2829","article-title":"Reversal agents in development for the new oral anticoagulants","volume":"126","author":"Costin J","year":"2014","unstructured":"Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S. Reversal agents in development for the new oral anticoagulants. Postgrad Med. 2014, 126:19-24. 10.3810\/pgm.2014.11.2829","journal-title":"Postgrad Med"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly SJ","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW, et al.. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016, 375:1131-41. 10.1056\/NEJMoa1607887","journal-title":"N Engl J Med"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.633","article-title":"Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban","volume":"56","author":"Chang M","year":"2016","unstructured":"Chang M, Yu Z, Shenker A, et al.. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016, 56:637-45. 10.1002\/jcph.633","journal-title":"J Clin Pharmacol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff J","year":"2013","unstructured":"Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013, 52:243-54. 10.1007\/s40262-013-0034-0","journal-title":"Clin Pharmacokinet"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0331-5","article-title":"Use of new oral anticoagulants in antiphospholipid syndrome","volume":"15","author":"Arachchillage DJ","year":"2013","unstructured":"Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep. 2013, 15:331. 10.1007\/s11926-013-0331-5","journal-title":"Curr Rheumatol Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/73636-role-of-direct-oral-anticoagulation-agents-as-thromboprophylaxis-in-antiphospholipid-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:41Z","timestamp":1707507341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/73636-role-of-direct-oral-anticoagulation-agents-as-thromboprophylaxis-in-antiphospholipid-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,24]]},"references-count":111,"URL":"https:\/\/doi.org\/10.7759\/cureus.19009","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,24]]}}}